 SOUTH SAN FRANCISCO, Calif., March 10, 2021 GLOBE NEWSWIRE -- Atreca, Inc. Atreca NASDAQ: BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 15 and May 17 21 2021. The poster will describe the design of the companys ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 as monotherapy and in combination with pembrolizumab in patients with solid tumor cancers. 